PT  - JOURNAL ARTICLE
AU  - Annavajhala, Medini K.
AU  - Mohri, Hiroshi
AU  - Wang, Pengfei
AU  - Nair, Manoj
AU  - Zucker, Jason E.
AU  - Sheng, Zizhang
AU  - Gomez-Simmonds, Angela
AU  - Kelley, Anne L.
AU  - Tagliavia, Maya
AU  - Huang, Yaoxing
AU  - Bedford, Trevor
AU  - Ho, David D.
AU  - Uhlemann, Anne-Catrin
TI  - Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York
AID  - 10.1101/2021.02.23.21252259
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.23.21252259
4099  - http://medrxiv.org/content/early/2021/08/04/2021.02.23.21252259.short
4100  - http://medrxiv.org/content/early/2021/08/04/2021.02.23.21252259.full
AB  - Recent months have seen surges of SARS-CoV-2 infection across the globe with considerable viral evolution1-3. Extensive mutations in the spike protein may threaten efficacy of vaccines and therapeutic monoclonal antibodies4. Two signature mutations of concern are E484K, which plays a crucial role in the loss of neutralizing activity of antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here, we report the emergence of variant lineage B.1.526 that contains E484K and its alarming rise to dominance in New York City in early 2021. This variant is partially or completely resistant to two therapeutic monoclonal antibodies in clinical use and less susceptible to neutralization by convalescent plasma or vaccinee sera, posing a modest antigenic challenge. The B.1.526 lineage has now been reported from all 50 states in the US and numerous other countries. B.1.526 rapidly replaced earlier lineages in New York upon its emergence, with an estimated transmission advantage of 35%. Such transmission dynamics, together with the relative antibody resistance of its E484K sub-lineage, likely contributed to the sharp rise and rapid spread of B.1.526. Although SARS-CoV-2 B.1.526 initially outpaced B.1.1.7 in the region, its growth subsequently slowed concurrent with the rise of B.1.1.7 and ensuing variants.Competing Interest StatementP.W., M.S.N., Y.H., and D.D.H. are inventors on a provisional patent application on monoclonal antibodies against SARS-CoV-2. D.D.H. is a member of the scientific advisory board of Brii Biosciences, which has provided a grant to Columbia University to support this and other studies on SARS-CoV-2. A.-C.U. and D.D.H. have received funding from Merck & Co. unrelated to this study.Funding StatementBiospecimens utilized for this research were obtained from the Columbia University Biobank (CUB), supported by the Irving Institute for Clinical and Translational Research, home to Columbia University Clinical and Translational Science Award (CTSA) funded through Grant Number UL1TR001873. This work was in part funded by NIH/NIDA grant U01 DA053949 (ACU, MKA) and by support from Andrew & Peggy Cherng, Samuel Yin, Barbara Picower and the JBP Foundation, Brii Biosciences, Roger & David Wu, and the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Columbia University Institutional Review Board (protocol number AAAT0123).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 genomes generated as part of this study have been submitted to GISAID under submitter ID mka2136 and NCBI GenBank under BioProject PRJNA751551. https://nextstrain.org/groups/blab/ncov/ny/B.1.526